Vimarsana
Biggest News Aggregation in the World

Page 3 - Topline Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topline Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topline Phase Today - Breaking & Trending Today

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update - Vimarsana News

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

WALTHAM, Mass., Nov. 04, 2022 -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct... | November 4, 2022

CinCor Reports Second Quarter Financial Results and Provides Corporate Update - Vimarsana News

CinCor Reports Second Quarter Financial Results and Provides Corporate Update

Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension ... | August 8, 2022

Prothena : Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights - Form 8-K - Vimarsana News

Prothena : Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights - Form 8-K

Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights •Net cash used in operating... | February 17, 2022

Pipeline Report: Several blockbuster drugs are poised to go bigger and broader - Vimarsana News

Pipeline Report: Several blockbuster drugs are poised to go bigger and broader

Therapies in the oncology, neurology and autoimmune disease pipelines could soon pose challenges to existing standards of care.

Friedreich's Ataxia - Vimarsana News

Friedreich's Ataxia

Goldman Sachs started coverage of Horizon Pharma PLC (NASDAQ: HZNP) with a Buy rating and $24 target price, implying 34 percent upside, on the strength of its emerging orphan franchise. 'Attractive' Story "We view HZNP as an attractive SOTP story in transformation with management using the strong... Read More... Don't Miss Any Updates! News Directly in Your Inbox Subscribe to: